BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 19, 2024
See today's BioWorld
Home
» Visionary Eyetech Saw Aptamers' Value, Turned Macugen Into Gold
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Visionary Eyetech Saw Aptamers' Value, Turned Macugen Into Gold
April 26, 2004
By
Randy Osborne
No Comments
Eyetech Pharmaceuticals Inc.'s CEO David Guyer typically is humble when he talks about the company's landmark potential $750 million deal in late 2002 with Pfizer Inc. for Macugen, the in-licensed aptamer for age-related macular degeneration.
BioWorld